CTEV

Claritev (the former MultiPlan) is a healthcare cost-containment processor whose equity is now a thin, highly levered stub sitting on top of a distressed balance sheet. FY2025 revenue of $965M grew a modest +3.7%, and operating income turned positive at $28.8M (a 3.0% margin), but that is where the good news ends. The company carries $4.61B of long-term debt against just $16.8M of cash and reports negative stockholders' equity of -$174M with a -$2.43B accumulated deficit. Liabilities/equity is meaningless at -29x because the equity is underwater. The $28.8M of operating income cannot come close to servicing the interest on $4.6B of debt, which is exactly why net income was -$284M and diluted EPS -$17.30 despite positive operations.

The headline valuation — a 0.6x P/S on a $540M market cap — is a classic value trap. On an enterprise basis the debt dominates: adding ~$4.6B of net debt puts EV near $5B, or roughly 5x sales and ~175x operating income, so the business is not cheap once you pay for the capital structure. Operating cash flow of $117M is real, but capex of $130M means free cash flow was negative, leaving nothing to delever. With ~39x debt-to-OCF, this is a refinancing story, and any adverse move in rates or credit access threatens the equity directly.